Detalles de la búsqueda
1.
Relating Lipoprotein(a) Concentrations to Cardiovascular Event Risk After Acute Coronary Syndrome: A Comparison of 3 Tests.
Circulation
; 149(3): 192-203, 2024 01 16.
Artículo
en Inglés
| MEDLINE | ID: mdl-37632469
2.
2023 AHA/ACC/ACCP/ASPC/NLA/PCNA Guideline for the Management of Patients With Chronic Coronary Disease: A Report of the American Heart Association/American College of Cardiology Joint Committee on Clinical Practice Guidelines.
Circulation
; 148(9): e9-e119, 2023 08 29.
Artículo
en Inglés
| MEDLINE | ID: mdl-37471501
3.
Transiently achieved very low LDL-cholesterol levels by statin and alirocumab after acute coronary syndrome are associated with cardiovascular risk reduction: the ODYSSEY OUTCOMES trial.
Eur Heart J
; 2023 Mar 05.
Artículo
en Inglés
| MEDLINE | ID: mdl-36879424
4.
Apolipoprotein B, Residual Cardiovascular Risk After Acute Coronary Syndrome, and Effects of Alirocumab.
Circulation
; 146(9): 657-672, 2022 08 30.
Artículo
en Inglés
| MEDLINE | ID: mdl-35770629
5.
Recurrent Atherosclerotic Cardiovascular Disease Events Potentially Prevented with Guideline-Recommended Cholesterol-Lowering Therapy following Myocardial Infarction.
Cardiovasc Drugs Ther
; 2023 Apr 13.
Artículo
en Inglés
| MEDLINE | ID: mdl-37052867
6.
The Projected Impact of Population-Wide Achievement of LDL Cholesterol <70 mg/dL on the Number of Recurrent Events Among US Adults with ASCVD.
Cardiovasc Drugs Ther
; 37(1): 107-116, 2023 02.
Artículo
en Inglés
| MEDLINE | ID: mdl-34599698
7.
Association between P-pulmonale and respiratory morbidity in COPD: a secondary analysis of the BLOCK-COPD trial.
BMC Pulm Med
; 23(1): 434, 2023 Nov 09.
Artículo
en Inglés
| MEDLINE | ID: mdl-37946165
8.
Alirocumab after acute coronary syndrome in patients with a history of heart failure.
Eur Heart J
; 43(16): 1554-1565, 2022 04 19.
Artículo
en Inglés
| MEDLINE | ID: mdl-34922353
9.
Trends in Recurrent Coronary Heart Disease After Myocardial Infarction Among US Women and Men Between 2008 and 2017.
Circulation
; 143(7): 650-660, 2021 02 16.
Artículo
en Inglés
| MEDLINE | ID: mdl-32951451
10.
Clinical Efficacy and Safety of Alirocumab After Acute Coronary Syndrome According to Achieved Level of Low-Density Lipoprotein Cholesterol: A Propensity Score-Matched Analysis of the ODYSSEY OUTCOMES Trial.
Circulation
; 143(11): 1109-1122, 2021 03 16.
Artículo
en Inglés
| MEDLINE | ID: mdl-33438437
11.
Addressing Social Determinants of Health in the Care of Patients With Heart Failure: A Scientific Statement From the American Heart Association.
Circulation
; 141(22): e841-e863, 2020 06 02.
Artículo
en Inglés
| MEDLINE | ID: mdl-32349541
12.
Peripheral Artery Disease and Venous Thromboembolic Events After Acute Coronary Syndrome: Role of Lipoprotein(a) and Modification by Alirocumab: Prespecified Analysis of the ODYSSEY OUTCOMES Randomized Clinical Trial.
Circulation
; 141(20): 1608-1617, 2020 05 19.
Artículo
en Inglés
| MEDLINE | ID: mdl-32223446
13.
Alirocumab and Cardiovascular Outcomes after Acute Coronary Syndrome.
N Engl J Med
; 379(22): 2097-2107, 2018 11 29.
Artículo
en Inglés
| MEDLINE | ID: mdl-30403574
14.
An Interprofessional Collaborative Practice Can Reduce Heart Failure Hospital Readmissions and Costs in an Underserved Population.
J Card Fail
; 27(11): 1185-1194, 2021 11.
Artículo
en Inglés
| MEDLINE | ID: mdl-33991685
15.
Risk for recurrent cardiovascular disease events among patients with diabetes and chronic kidney disease.
Cardiovasc Diabetol
; 20(1): 58, 2021 03 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-33648518
16.
Effect of alirocumab on major adverse cardiovascular events according to renal function in patients with a recent acute coronary syndrome: prespecified analysis from the ODYSSEY OUTCOMES randomized clinical trial.
Eur Heart J
; 41(42): 4114-4123, 2020 11 07.
Artículo
en Inglés
| MEDLINE | ID: mdl-32820320
17.
Lipoprotein(a) lowering by alirocumab reduces the total burden of cardiovascular events independent of low-density lipoprotein cholesterol lowering: ODYSSEY OUTCOMES trial.
Eur Heart J
; 41(44): 4245-4255, 2020 11 21.
Artículo
en Inglés
| MEDLINE | ID: mdl-33051646
18.
Effect of alirocumab on cardiovascular outcomes after acute coronary syndromes according to age: an ODYSSEY OUTCOMES trial analysis.
Eur Heart J
; 41(24): 2248-2258, 2020 06 21.
Artículo
en Inglés
| MEDLINE | ID: mdl-31732742
19.
Effect of Alirocumab on Stroke in ODYSSEY OUTCOMES.
Circulation
; 140(25): 2054-2062, 2019 12 17.
Artículo
en Inglés
| MEDLINE | ID: mdl-31707788
20.
Effect of Alirocumab on Mortality After Acute Coronary Syndromes.
Circulation
; 140(2): 103-112, 2019 07 09.
Artículo
en Inglés
| MEDLINE | ID: mdl-31117810